Ribocure Pharmaceuticals AB

Stay tuned to hear our oral presentation at the upcoming European Society for Cardiology (ESC) August 30 - September 2, where Ribo will present the first clinical data from our completed Ph1 study of world´s first and most advanced hemostasis-sparing antithrombotic Factor XI (FXI) targeting siRNA asset RBD4059, based on our RIBO-GalSTAR™ technology. The presentation will be given by Dr, Anders Gabrielsen, MD, DMSc, FESC, our Global VP of Clinical Development.   Our RIBO-GalSTAR™ platform is currently the background of five different clinical stage assets and has consistently shown potent and durable knock-down of target disease-causing genes with good translation from preclinical models to human.   We have now shown for RBD4059, the clinical efficacy in terms of potency and duration is substantially more pronounced in humans, compared to rodents and non-human primates, augmenting RBD4059’s best-in-class potential as a new therapeutic option for patients in need of safe thrombo-protective therapies.   RBD4059 received recently Ph2 EMA CTA approval based on emerging Ph1 data, to enter our target population in Sweden with First Dose planned in August 2024.   #ESCCongress #siRNA https://lnkd.in/dzjvjHNS Suzhou Ribo Life Science Co., Ltd

Ribocure is hiring! We have now an open position for a QA Specialist. Please read more below and welcome with your application. https://lnkd.in/dr6wY3me

Proud of showing our great in-house phase 2 facility, the Ribocure Clinic, specialized on cardiometabolic Proof of Principle studies. We kick-started the day by being part of an interesting and cross-diciplinary panel discussion on "Powering Innovation Culture". Thank you for a great arrangement of the first GoCo Open House GoCo Health Innovation City #ribocureclinic #gocohic #innovation Photo cred: Andreas Jacobsson

Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the world´s first siRNA drug targeting Factor XI: RBD4059 On May 27, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the world’s first and most advanced anti-thrombotic siRNA drug, RBD4059 targeting FXI. The trial will evaluate safety, pharmacokinetics and pharmacodynamics of its novel siRNA asset RBD4059, in patients with stable coronary artery disease. This is a randomized, double-blind, placebo-controlled phase II trial to evaluate safety, pharmacokinetics and pharmacodynamics of RBD4059 in participants with stable coronary artery disease. The study aims to demonstrate proof of principle and confirm dose response in the target population. The study will be run at Ribocure Clinic, a specialized phase II unit for high quality functional imaging proof of principle trials, based in GoCo Health Innovation City, Sweden. Read the full news here: https://lnkd.in/esrJemtd #Ribocureclinic #clinicaltrials #siRNA #gocohic #fxi Suzhou Ribo Life Science Co., Ltd

Meet the Ribocure team tomorrow at the GoCo Open House! We will open up for tours in our own Phase 2 clinical trial unit and office on floor 5 in the GoCo Clinic building. Hope to see you!

RIBO RECEIVES GRANTED PATENTS FOR PHASE 2 HBV SIRNA ASSET RBD1016 IN UNITED STATES AND EUROPE   Ribocure Pharmaceuticals/Suzhou Ribo Life Science Co. Ltd. ("Ribo") announce Notice of Allowance issued respectively by US Patent Office and European Patent Office for patent applications covering the anti-hepatitis B siRNA drug RBD1016. With the approved patents in US and Europe, and with the previous authorizations in six major countries/regions, including China and Japan, Ribo´s strategy to support the use of RBD1016 globally for treatment of Chronic Hepatitis B infection (CHB) continues to execute. Ribo holds already a strong patent portfolio for both its individual programs and its proprietary GalNAc-siRNA liver targeting platform, RIBO-GalSTAR.  Link to full article: https://lnkd.in/dXxKHhBZ #HBV #oligonucleotides #gocohic #Riboclinic Suzhou Ribo Life Science Co., Ltd

Join us in celebrating Clinical Trials Day!   Today we highlight the Clinical Trials Day and the importance of clinical research at Ribocure Pharmaceuticals and Ribocure Clinic. Ribocure Clinic is our specialized clinical trial unit with highly trained medical research staff for Ph2 trials in cardiovascular, pulmonary, renal and liver disease, where advanced imaging and functional assessments are applied. Read more about Ribocure Clinic, based in GoCo Health Innovation City, Mölndal, Sweden: https://lnkd.in/djaVcNu7   #ClinicalTrialsDay #gocohic #lifescience #ribocureclinic #siRNA #oligonucleotides @ribocurepharmaceuticals @suzhouribolifescience

Open call for a Business Development Manager at Ribocure. Welcome to apply!

Don't miss out on this fantastic opportunity to join a great team at Ribocure Pharmaceuticals.